

Príomhoifigeach Cliniciúil Oifig an Phríomhoifigigh Cliniciúil

Ospidéal Dr Steevens, Lána Steevens Baile Átha Cliath 8, D08 W2A8

Chief Clinical Officer Office of the Chief Clinical Officer

Dr Steevens Hospital, Steevens Lane t 01 635 2000 Dublin 8, D08 W2A8

www.hse.ie @hselive

e cco@hse.ie

BY EMAIL ONLY

Deputy Róisín Shortall Dáil Éireann Leinster House Kildare Street Dublin 2

6th April 2022

PQ 17886/22 Deputy Róisín Shortall - To ask the Minister for Health his plans, if any, for a communications campaign in respect of accessing Covid-19 antiviral treatments; the steps he has taken to ensure patients are aware of the pathways to treatment; and if he will make a statement on the matter.

Dear Deputy Shortall,

Thank you for your representation.

Our communications strategy has worked firstly with clinical networks, to allow them to establish patient pathways and provide clear support and guidance to the people in their care, with advocacy groups who represent current and future needs of patients, and with people in the community through news media, updated web content on HSE.ie, and on social media.

The HSE works directly with a supportive network of advocacy groups, who represent patients and people who are likely to benefit from these therapeutics and have shared a range of updates with this group, for onward sharing with their networks and members.

As each product becomes available, detailed web content is developed and promoted, for an example relating to the single product currently available in Ireland, Sotrovimab, please see the following link:

https://www2.hse.ie/conditions/covid19/symptoms/treatments-for-covid-19/

As new products are delivered or approved for use, they will be added to this page – the next product due for availability in this group will be Paxlovid.

The information available is also shared through national and regional news media, with regular coverage of this topic ongoing, through HSE social media queries, posts and through our call centre at HSElive.

The HSE will continue our communications on this topic, extending them as the products available increase, and responding to feedback from patient and the public, from advocates and from our clinical colleagues, including General Practitioners through the IMO and the ICGP, and directly with Hospitals Groups.



I hope this provides you with assistance.

Yours sincerely

Sharon Hayden

General Manager Office of the CCO